market news - Unibest Industrial Co., Ltd.

Blogs

Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

market

Knowing that you are interested in market, we have listed articles on similar topics on the website for your convenience. As a professional manufacturer, we hope that this news can help you. If you are interested in learning more about the product, please feel free to contact us.

Oral SERD Therapy: Elacestrant's Impact on Metastatic Breast Cancer
2024-10-10

IntroductionBreast cancer remains a significant global health challenge, with over 2.3 million new cases diagnosed worldwide in 2022, according to the IARC. The disease burden is disproportionately higher in countries with medium or low levels of the Human Development Index (HDI), where access to in Read More
Alopecia Areata: More Than Just Hair Loss
2024-09-20

Alopecia areata (AA) is an autoimmune disorder that goes far beyond mere hair loss. While the physical manifestation of patchy or complete hair loss is its most visible symptom, the impact of AA extends deep into the psychological realm, affecting millions worldwide.Understanding Alopecia AreataAlop Read More
A $25 Billion Opportunity: Exploring the Enormous Market Impact of Deucravacitinib
2024-08-01

Deucravacitinib has emerged as a groundbreaking treatment for moderate-to-severe plaque psoriasis. As we at Unibest keep up with the current pharamceutical blockbusters, we're excited to explore the potential of this novel drug in the enormous oral systemic psoriasis drug market.A Milestone in Deut Read More
Market Expansion: Dapagliflozin Receives FDA Approval for Treating Type 2 Diabetes in Children
2024-06-13

AstraZeneca has announced on June 12, 2024, that Farxiga (dapagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) for improving glycemic control in children aged 10 years and above with type 2 diabetes (T2D). The FDA approval is based on the positive results from the Phase 3 Read More
Avacopan - Orphan Drug with a Growing Market
2024-06-07

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA-associated vasculitis) is a rare but serious autoimmune disease affecting small blood vessels. With a global prevalence estimated between 30-218 cases per million, it leads to inflammation of blood vessels and potential organ damage. C Read More
Scaling the Everest of Pharma Synthesis: A Deep Dive into Eribulin's Journey
2024-04-19

As one steps into the realm of pharmaceutical discovery, the name Eribulin, also known as Halaven, rings a powerful note. First approved in 2010 by Eisai, this non-peptide drug, intricate in its synthesis and impressive in the magnitude of its medical impact, has been nothing short of groundbreaking Read More
Market Analysis of Vibegron for the Treatment of Overactive Bladder
2024-01-02

Prevalence of OABAccording to Statistic Brain, an estimated 183 million people worldwide suffer from overactive bladder (OAB), with North America having the highest prevalence. In the U.S. alone, around 66.6 million people experience OAB symptoms, suggesting a significant market potential for OAB tr Read More
Forecasting the Global Demand for Ubrogepant
2023-10-19

In the dynamic realm of the pharmaceutical industry, where the drive for improved patient outcomes meets the reality of a global market, understanding and forecasting demand is key. Unibest has developed a step-by-step approach to calculating the market potential for specific pharmaceuticals. In thi Read More
Lenacapavir: Market Analysis of the First-in-Class Capsid Inhibitor
2023-10-13

In August 2022, Gilead announced that the European Commission (EC) has granted marketing authorization for Sunlenca (Lenacapavir), an innovative treatment for adults with multi-drug resistant HIV infection. The treatment works in combination with other antiretroviral(s) when it isn't Read More